164 related articles for article (PubMed ID: 37132182)
1. Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.
Thompson JR; Lai-Kwon J; Morton RL; Guminski AD; Gonzalez M; Atkinson V; Sandhu S; Brown MP; Menzies AM; McArthur GA; Lo SN; Long GV; Bartula I
Immunotherapy; 2023 Jun; 15(8):593-610. PubMed ID: 37132182
[TBL] [Abstract][Full Text] [Related]
2. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis.
Su M; Yang Y; Wang P
Immunopharmacol Immunotoxicol; 2023 Dec; 45(6):761-769. PubMed ID: 37228242
[TBL] [Abstract][Full Text] [Related]
4. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204).
Tawbi HA; Forsyth PA; Hodi FS; Lao CD; Moschos SJ; Hamid O; Atkins MB; Lewis K; Thomas RP; Glaspy JA; Jang S; Algazi AP; Khushalani NI; Postow MA; Pavlick AC; Ernstoff MS; Reardon DA; Puzanov I; Kudchadkar RR; Tarhini AA; Sumbul A; Rizzo JI; Margolin KA
Neuro Oncol; 2021 Nov; 23(11):1961-1973. PubMed ID: 33880555
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.
Tawbi HA; Forsyth PA; Hodi FS; Algazi AP; Hamid O; Lao CD; Moschos SJ; Atkins MB; Lewis K; Postow MA; Thomas RP; Glaspy J; Jang S; Khushalani NI; Pavlick AC; Ernstoff MS; Reardon DA; Kudchadkar R; Tarhini A; Chung C; Ritchings C; Durani P; Askelson M; Puzanov I; Margolin KA
Lancet Oncol; 2021 Dec; 22(12):1692-1704. PubMed ID: 34774225
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
Di Giacomo AM; Chiarion-Sileni V; Del Vecchio M; Ferrucci PF; Guida M; Quaglino P; Guidoboni M; Marchetti P; Simonetti E; Santangelo F; Amato G; Covre A; Camerini R; Valente M; Mandalà M; Giannarelli D; Calabrò L; Maio M
Eur J Cancer; 2024 Mar; 199():113531. PubMed ID: 38271746
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study.
Kirkwood JM; Kottschade LA; McWilliams RR; Khushalani NI; Jang S; Hallmeyer S; McDermott DF; Tawbi H; Che M; Lee CH; Ritchings C; Le TK; Park B; Ramsey S
Immunotherapy; 2024 Jan; 16(1):29-42. PubMed ID: 37937397
[TBL] [Abstract][Full Text] [Related]
9. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Tawbi HA; Forsyth PA; Algazi A; Hamid O; Hodi FS; Moschos SJ; Khushalani NI; Lewis K; Lao CD; Postow MA; Atkins MB; Ernstoff MS; Reardon DA; Puzanov I; Kudchadkar RR; Thomas RP; Tarhini A; Pavlick AC; Jiang J; Avila A; Demelo S; Margolin K
N Engl J Med; 2018 Aug; 379(8):722-730. PubMed ID: 30134131
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life results from the phase III CheckMate 067 study.
Schadendorf D; Larkin J; Wolchok J; Hodi FS; Chiarion-Sileni V; Gonzalez R; Rutkowski P; Grob JJ; Cowey CL; Lao C; Wagstaff J; Callahan MK; Postow MA; Smylie M; Ferrucci PF; Dummer R; Hill A; Taylor F; Sabater J; Walker D; Kotapati S; Abernethy A; Long GV
Eur J Cancer; 2017 Sep; 82():80-91. PubMed ID: 28651159
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
13. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids.
Manacorda S; Carmena MT; Malone C; Linh Le HM; Furness AJS; Larkin J; Schmitt AM
Eur J Cancer; 2023 Jul; 188():98-107. PubMed ID: 37229837
[TBL] [Abstract][Full Text] [Related]
15. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
Serra-Bellver P; Versluis JM; Oberoi HK; Zhou C; Slattery TD; Khan Y; Patrinely JR; Pires da Silva I; Martínez-Vila C; Cook N; Graham DM; Carlino MS; Menzies AM; Arance AM; Johnson DB; Long GV; Pickering L; Larkin JMG; Blank CU; Lorigan P
Eur J Cancer; 2022 Nov; 176():121-132. PubMed ID: 36215945
[TBL] [Abstract][Full Text] [Related]
16. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
McDermott DF; Shah R; Gupte-Singh K; Sabater J; Luo L; Botteman M; Rao S; Regan MM; Atkins M
Qual Life Res; 2019 Jan; 28(1):109-119. PubMed ID: 30191365
[TBL] [Abstract][Full Text] [Related]
17. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
18. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
McDonald MA; Sanghvi P; Bykowski J; Daniels GA
BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).
Nathan P; Ascierto PA; Haanen J; Espinosa E; Demidov L; Garbe C; Guida M; Lorigan P; Chiarion-Sileni V; Gogas H; Maio M; Fierro MT; Hoeller C; Terheyden P; Gutzmer R; Guren TK; Bafaloukos D; Rutkowski P; Plummer R; Waterston A; Kaatz M; Mandala M; Marquez-Rodas I; Muñoz-Couselo E; Dummer R; Grigoryeva E; Young TC; Schadendorf D
Eur J Cancer; 2019 Sep; 119():168-178. PubMed ID: 31445199
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E; Zimmer L; Hassel JC; Fluck M; Eigentler TK; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kiecker F; Dippel E; Roesch A; Ziemer M; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2022 Oct; 400(10358):1117-1129. PubMed ID: 36099927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
